Cipla, Serum Institute agreement

Signs exclusive distribution agreement for flu vaccine ‘Nasovac-S’ for India

Cipla has signed an agreement with Serum Institute of India (SII) to exclusively market flu vaccine Nasovac-S in India. Under this agreement, SII will develop and manufacture the vaccine, and Cipla will exclusively market it in India. The vaccine will be manufactured in Serum’s world class production facilities approved by the WHO.

Commenting on the agreement, Subhanu Saxena, Managing Director and Global CEO, Cipla said, “We are delighted to have entered into a strategic partnership with SII in India. This collaboration is aligned with our commitment to access to affordable healthcare. This partnership is a significant step towards making preventative healthcare accessible to a large number of Indians through Cipla痴 strong countrywide salesforce.”

Having initiated the approval process with the European Medicines Authority for marketing the products developed and manufactured by SII, Cipla is now forging ahead looking at other markets where the company has a strong presence.

The advantage of Nasovac-S vaccine is that it is administered through the nasal route and is therefore painless. It increases indirect protection through herd immunity and protects against drifted viruses.

CiplaEuropean Medicines AuthoritySerum Institute of IndiaSubhanu Saxena